^
Association details:
Biomarker:BRAF V600E
Cancer:Melanoma
Drug:belvarafenib (RG6185) (pan-RAF inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Title:

Belvarafenib penetrates the BBB and shows potent antitumor activity in a murine melanoma brain metastasis model

Published date:
02/10/2023
Excerpt:
Belvarafenib strongly suppressed melanoma in BRAF V600E mutant A375SM tumor-bearing mice. It also significantly inhibited tumor growth in NRAS mutant SK-MEL-30 and K1735 tumor-bearing mice and synergized to enhance the antitumor activity combined with cobimetinib or atezolizumab.
DOI:
10.1007/s10585-023-10198-7
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

Antitumor activity of belvarafenib in melanoma brain metastasis and NRAS mutation melanoma models

Published date:
03/10/2021
Excerpt:
Belvarafenib showed excellent anti-tumor activity in an orthotopic brain tumor model using melanoma cells. Belvarafenib significantly increased the overall survival of mice implanted intracranially with BRAF V600E A375SM melanoma cells.